{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:41:49Z","timestamp":1786372909737,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.2215\/cjn.04780709","type":"journal-article","created":{"date-parts":[[2009,12,7]],"date-time":"2009-12-07T19:15:02Z","timestamp":1260213302000},"page":"S95-S101","source":"Crossref","is-referenced-by-count":25,"title":["Is Lipid Control Necessary in Hemodialysis Patients?"],"prefix":"10.2215","volume":"4","author":[{"given":"Alfred K.","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20230601","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"R2-15-20230601","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(86)90597-0","article-title":"Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men","volume":"2","author":"Martin","year":"1986","journal-title":"Lancet"},{"key":"R3-15-20230601","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"R4-15-20230601","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R5-15-20230601","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R6-15-20230601","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities study","volume":"16","author":"Muntner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R7-15-20230601","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.ki.5001789","article-title":"Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival","volume":"70","author":"Williams","year":"2006","journal-title":"Kidney Int"},{"key":"R8-15-20230601","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1523-1755.1998.00005.x","article-title":"\u201cU\u201d curve association of blood pressure and mortality in hemodialysis patients","volume":"54","author":"Zager","year":"1998","journal-title":"Kidney Int"},{"key":"R9-15-20230601","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"R10-15-20230601","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-15-20230601","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"R12-15-20230601","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"R13-15-20230601","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"R14-15-20230601","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"R15-15-20230601","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"R16-15-20230601","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","article-title":"HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients","volume":"61","author":"Seliger","year":"2002","journal-title":"Kidney Int"},{"key":"R17-15-20230601","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2004.09.025","article-title":"HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients","volume":"45","author":"Mason","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R19-15-20230601","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","article-title":"Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study","volume":"65","author":"Cheung","year":"2004","journal-title":"Kidney Int"},{"key":"R21-15-20230601","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"R22-15-20230601","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0272-6386(12)80030-8","article-title":"Lipoprotein metabolism and renal failure","volume":"21","author":"Attman","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"R23-15-20230601","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/clinchem\/46.5.667","article-title":"Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease","volume":"46","author":"Hirany","year":"2000","journal-title":"Clin Chem"},{"key":"R24-15-20230601","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/ki.1992.411","article-title":"Severe defect in clearing postprandial chylomicron remnants in dialysis patients","volume":"42","author":"Weintraub","year":"1992","journal-title":"Kidney Int"},{"key":"R25-15-20230601","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","article-title":"Lipoprotein metabolism and lipid management in chronic kidney disease","volume":"18","author":"Kwan","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R26-15-20230601","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/S0021-9258(18)61656-4","article-title":"Transport of beta-very low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway","volume":"262","author":"Ellsworth","year":"1987","journal-title":"J Biol Chem"},{"key":"R27-15-20230601","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/01.ATV.19.10.2474","article-title":"Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins","volume":"19","author":"Cohn","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R28-15-20230601","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1161\/01.CIR.99.22.2852","article-title":"Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis","volume":"99","author":"Hodis","year":"1999","journal-title":"Circulation"},{"key":"R29-15-20230601","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"key":"R30-15-20230601","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2004.11.062","article-title":"Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease","volume":"45","author":"Hopkins","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R32-15-20230601","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT\u2014A randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"R33-15-20230601","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","article-title":"Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency","volume":"66","author":"Tonelli","year":"2004","journal-title":"Kidney Int"},{"key":"R34-15-20230601","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.nutr.18.1.297","article-title":"Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport","volume":"18","author":"Bruce","year":"1998","journal-title":"Annu Rev Nutr"},{"key":"R35-15-20230601","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R36-15-20230601","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R37-15-20230601","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1681\/ASN.V102332","article-title":"Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients","volume":"10","author":"Quaschning","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R38-15-20230601","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ki.1994.115","article-title":"Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?","volume":"45","author":"Maggi","year":"1994","journal-title":"Kidney Int"},{"key":"R39-15-20230601","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1523-1755.2005.00391.x","article-title":"Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease","volume":"68","author":"Ok","year":"2005","journal-title":"Kidney Int"},{"key":"R40-15-20230601","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","article-title":"Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis","volume":"6","author":"Kronenberg","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R41-15-20230601","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein (a) and coronary heart disease: Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"R42-15-20230601","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","article-title":"The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up","volume":"10","author":"Kronenberg","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R43-15-20230601","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1681\/ASN.2004110922","article-title":"High lipoprotein (a) levels and small apolipoprotein (a) size prospectively predict cardiovascular events in dialysis patients","volume":"16","author":"Longenecker","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R44-15-20230601","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch Intern Med"},{"key":"R45-15-20230601","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0021-9150(92)90177-I","article-title":"Differential effects of nicotinic acid in subjects with different LDL subclass patterns","volume":"95","author":"Superko","year":"1992","journal-title":"Atherosclerosis"},{"key":"R46-15-20230601","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"R47-15-20230601","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","article-title":"The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia","volume":"62","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"},{"key":"R48-15-20230601","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-9150(99)00410-4","article-title":"Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy","volume":"150","author":"Islam","year":"2000","journal-title":"Atherosclerosis"},{"key":"R49-15-20230601","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"key":"R50-15-20230601","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.CIR.0000050628.11305.30","article-title":"The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial","volume":"107","author":"Tepel","year":"2003","journal-title":"Circulation"},{"key":"R51-15-20230601","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S0085-2538(15)46619-0","article-title":"Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients","volume":"71","author":"Mune","year":"1999","journal-title":"Kidney Int Suppl"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-200912001-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:14Z","timestamp":1786369154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-200912001-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":48,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04780709","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}